Anton Daniel, MD
Internal Medicine · Newport, TNNPI 1700856135
Payments from drug & device makers
Across 957 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- GSK$1K
- AstraZeneca$1K
- Novo Nordisk$931
- Lilly USA, LLC$885
- Boehringer Ingelheim$819
- plus $8K from 47 others
What the payments were for
- Food & beverage$14,67299%
- Education$2171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$110
How this compares
$14,889 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 940 | $258,051 |
| JardianceEmpagliflozin | 647 | $226,731 |
| Repatha SureclickEvolocumab | 190 | $124,012 |
| MounjaroTirzepatide | 105 | $120,551 |
| FarxigaDapagliflozin Propanediol | 131 | $86,609 |
| Xtampza ErOxycodone Myristate | 159 | $82,395 |
| OzempicSemaglutide | 83 | $81,395 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 95 | $67,775 |
| KerendiaFinerenone | 78 | $67,135 |
| TrulicityDulaglutide | 59 | $54,303 |
| LinzessLinaclotide | 71 | $52,350 |
| VraylarCariprazine Hcl | 44 | $51,035 |
| Tresiba Flextouch U-200Insulin Degludec | 64 | $43,421 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $42,209 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 75 | $41,858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt, Abrysvo | $460 | $285,433984 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $819 | $261,284699 claims |
| Lilly USA, LLCMounjaro, Trulicity | $885 | $174,854164 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,427 | $120,129188 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $1,218 | $117,187179 claims |
| AbbVieLinzess, Vraylar | $552 | $103,384115 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $569 | $82,395159 claims |
| Novo NordiskOzempic | $931 | $81,39583 claims |
| BayerKerendia | $377 | $67,13578 claims |
| NovartisEntresto | $513 | $31,69078 claims |
| Johnson & JohnsonXarelto | $298 | $29,016151 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $505 | $28,77219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Newport
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.